References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrevalence of frailty among nursing home, according to different operational definitions.
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; GILLAIN, Sophie ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 216-217

Detailed reference viewed: 22 (3 ULiège)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge study.
Locquet, Médéa ULiege; Beaudart, Charlotte ULiege; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2016, April), 27(supplement 1), 129

Detailed reference viewed: 37 (4 ULiège)
Full Text
Peer Reviewed
See detailThe future prevalence of sarcopenia in Europe
Ethgen, Olivier ULiege; Tchoconte, C.; Beaudart, Charlotte ULiege et al

in Osteoporosis International (2016, April), 27(Supplement 1), 53-54

Detailed reference viewed: 75 (3 ULiège)
Peer Reviewed
See detailDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier ULiege; Cooper, Cyrus et al

in Drugs & Aging (2016), 33(2), 75-85

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been ... [more ▼]

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated [less ▲]

Detailed reference viewed: 30 (0 ULiège)
Full Text
Peer Reviewed
See detailOsteoporosis and sarcopenia: two diseases or one?
Reginster, Jean-Yves ULiege; Beaudart, Charlotte ULiege; Buckinx, Fanny ULiege et al

in Current Opinion in Clinical Nutrition & Metabolic Care (2016), 19(1), 31-6

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies ... [more ▼]

Purpose of review This article reviews recently published evidence for common pathways explaining bone and muscle wasting in normal ageing and pathological conditions. Recent findings Numerous studies support the concept of a bone–muscle unit, where constant cross-talking between the two tissues takes place, involving molecules released by the skeletal muscle secretome, which affects bone, and osteokines secreted by the osteoblasts and osteocytes, which, in turn, impact muscle cells. Summary New chemical entities aiming at concomitantly treating osteoporosis and sarcopenia could be developed by targeting pathways that centrally regulate bone and muscle or emerging pathways that facilitate the communication between the two tissues. [less ▲]

Detailed reference viewed: 29 (3 ULiège)
Full Text
Peer Reviewed
See detailDeterminants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Cavalier, Etienne ULiege et al

in Osteoporosis International (2016), 27

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 ... [more ▼]

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. Introduction The aim of this study is to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Methods General practitioners (GPs) having at least one patient in a nursing home in Liège, Belgium, were asked to complete the survey. Results A total of 119 GPs participated in the survey. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. The main reasons for prescribing vitamin D cited by GPs who do so systematically are as follows: because they believe nursing home residents are mostly deficient in vitamin D status (92.1 %), because they believe that vitamin D supplementation prevents osteoporotic fractures (77.8 %), and because vitamin D supplementation is recommended by various scientific societies (38.1 %). GPs who only prescribe vitamin D supplementation in some patients mainly do so following a diagnosis of osteoporosis (82.4 %), on the basis the 25(OH)D level (78.4 %), in the case of history of fracture (54.9 %) or after a recent fracture (43.4 %). Surprisingly, 16 physicians (31.4 %) only prescribe vitamin D when they think of it. Interestingly, while 40.7% of GPs always prescribe the same dose of vitamin D, the remaining 59.3 % prescribe a dose that will mainly depend on the results of the 25(OH)D level (94.0 %), the patient’s bone health (49.3 %), or history of fracture (43.3 %). Conclusions More than half of GPs systematically prescribe vitamin D to their patients living in nursing homes. The other GPs usually prescribe vitamin D following the result of the vitamin D status or after a diagnosis of osteoporosis. [less ▲]

Detailed reference viewed: 52 (15 ULiège)
Full Text
Peer Reviewed
See detailCritical analytical evaluation of promising markers for sarcopenia
Cavalier, Etienne ULiege; Beaudart, Charlotte ULiege; Buckinx, Fanny ULiege et al

in European Geriatric Medicine (2016), 7(3), 239-242

We tested and validated irisin (IRI), myostatin (MYO), PIIINP, osteoglycin (OGN), TMEM119 (TMEM) and activin A (AA) and established the analytical performance, reference range and stability (considered ... [more ▼]

We tested and validated irisin (IRI), myostatin (MYO), PIIINP, osteoglycin (OGN), TMEM119 (TMEM) and activin A (AA) and established the analytical performance, reference range and stability (considered unstable if more than 20% increase/decrease in the levels was observed in more than 10% of the samples). We were unable to obtain a valuable calibration curve with the Cusabio kits (TMEME and OGN). Coefficient of variation (CV) was too high for IRI (CV 17-30%), but were ≤ 10% for the 3 other analytes. AA and MYO were stable up to 3 months at -20 °C and -80 °C in serum or EDTA plasma and up to 6 months at -80 8C. PIIINP was stable only 1 month in EDTA plasma (but not in serum) at -20 °C or -80 8C. After 3 months of storage, PIIINP was not stable anymore, in serum or EDTA plasma, at -20 °C or -80 8C. Surprisingly, after 6 months at -80 8C, results returned in the ± 20% for both serum and EDTA plasma. PIIINP levels did not differ between men and women and the RR was (median, 90% CI) 1.2 (0.8-1.6)-6.0 (5.6-6.4) μg/L. The RR for MYO was 845 (437-1312)-6067 (5524-6552) pg/mL for men and 600 (268-1027)-4438 (4026-4837) pg/mL for women and the RR for AA was 177 (132-210)-622 (580-661) pg/mL for men and 98 (49-147)-480 (430-525) pg/mL for women. PIIINP and AA but not MYO accumulated in CKD as values observed in 10 hemodialyzed patients were higher than in normal individuals. © 2015 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved. [less ▲]

Detailed reference viewed: 23 (0 ULiège)
Full Text
Peer Reviewed
See detailGrip strength measurement: Towards a standardized approach in sarcopenia research and practice
Schaap, L. A.; Fox, B.; Henwood, T. et al

in European Geriatric Medicine (2016), 7(3), 247-255

Introduction: Grip strength is a well-accepted measure of muscle strength. A standardized protocol for the measurement of grip strength has been proposed in 2011 to enable consistent measurement of grip ... [more ▼]

Introduction: Grip strength is a well-accepted measure of muscle strength. A standardized protocol for the measurement of grip strength has been proposed in 2011 to enable consistent measurement of grip strength and comparisons between studies. It is unknown whether this protocol has been adopted in sarcopenia research and practice. The aim of the study was to provide insight into current measurement practice, including the use of cut-off values for low muscle strength. Methods: A systematic review of the literature was conducted, followed by a methodological quality assessment and extraction of relevant data. Inclusion criteria included a description of the grip strength protocol, EWGSOP standards were used to define sarcopenia, data was collected after 2010 and participants were 65 years and older. Results: Twenty-seven observational papers were included in the review. The methodological quality was acceptable/good. Overall, information about the protocol was limited with a large variability in measurement approach. Most non-Asian studies used cut-off values for low grip strength of 30 kg for men and 20 kg for women. Asian studies showed more variability in choice of cut-off values. Discussion: The proposed grip strength measurement protocol has been poorly adopted since its publication. Although there seems to be some agreement on cut-off values in non-Asian studies, proposed cut-off values need to be evaluated in specific diseases and settings and its predictive abilities regarding outcomes such as mobility limitations and falls needs to be determined. Asian research on cut-off values is still ongoing. © 2015 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved. [less ▲]

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailA comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement
Blain, H.; Masud, T.; Dargent-Molina, P. et al

in European Geriatric Medicine (2016), 7(6), 519-525

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest ... [more ▼]

Prevention of fragility fractures in older people has become a public health priority, although the most appropriate and cost-effective strategy remains unclear. In the present statement, the Interest group on falls and fracture prevention of the European union geriatric medicine society (EUGMS), in collaboration with the International association of gerontology and geriatrics for the European region (IAGG-ER), the European union of medical specialists (EUMS), the Fragility fracture network (FFN), the International osteoporosis foundation (IOF) – European society for clinical and economic aspects of osteoporosis and osteoarthritis (ECCEO), outlines its views on the main points in the current debate in relation to the primary and secondary prevention of falls, the diagnosis and treatment of bone fragility, and the place of combined falls and fracture liaison services for fracture prevention in older people. © 2016 [less ▲]

Detailed reference viewed: 59 (0 ULiège)
Full Text
Peer Reviewed
See detailRelationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Petermans, Jean ULiege et al

in Aging Clinical and Experimental Research (2016), 28(6), 1149-57

Background The aim of this study was to assess the relationship between frailty and a large number of indicators related to physical and muscular performance as well as quality of life. Methods This is an ... [more ▼]

Background The aim of this study was to assess the relationship between frailty and a large number of indicators related to physical and muscular performance as well as quality of life. Methods This is an analysis of data collected at baseline in the Sample of Elderly Nursing home Individuals: an Observational Research (SENIOR) cohort including nursing home residents. Subjects are volunteer, oriented and able to walk (walking assistance allowed) nursing home residents in Belgium. A large number of demographic and clinical characteristics, including physical and muscular performance, were collected from each patient. The prevalence of frailty in this population was assessed using Fried’s definition. Results In total, 662 subjects are included in this analysis. The mean age of the sample is 83.2 ± 8.99 years, and 484 (73.1 %) are women. In this population of nursing home residents, the prevalence of frailty is 25.1 %, pre-frailty, 59.8 % and robustness, 15.1 %. Compared to non-frail subjects, frail subjects have lower physical and muscular performances and a lower quality of life. Conclusion Frailty, according to Fried’s definition, seems to be associated with several clinical indicators suggesting a higher level of disability and an increased propensity to develop major clinical consequences. Follow-up data of the SENIOR cohort will be helpful in confirming these findings, establishing cause–effect relationships and identifying the most predictive components of physical frailty for adverse outcomes in nursing homes. [less ▲]

Detailed reference viewed: 53 (16 ULiège)
Full Text
Peer Reviewed
See detailSarcopenia as a public health problem
Bruyère, Olivier ULiege; Beaudart, Charlotte ULiege; Locquet, Médéa ULiege et al

in European Geriatric Medicine (2016), 7(3), 272-5

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an ... [more ▼]

The importance of a health problem is based on its current and expected prevalence, its clinical and economic consequences, the social status of people affected by the problem and the availability of an effective treatment. In this paper, we review the main current literature on sarcopenia in order to assess whether this geriatric syndrome could be considered as a major public health problem. Our review highlights that based on its prevalence, its clinical consequences, the limitations of the current available treatments as well as on the fact that many frail patients are affected by this geriatric syndrome, sarcopenia should be considered as a health priority by all interested parties in order to reduce its burden. [less ▲]

Detailed reference viewed: 56 (15 ULiège)
Full Text
See detailIl n'est jamais trop tard pour apprendre à (bien) lire ... Les essais croisés
Slomian, Justine ULiege; Bruyère, Olivier ULiege

in Vaisseaux, Coeur, Poumons (2016), 21(9), 34-36

Detailed reference viewed: 12 (0 ULiège)
Full Text
See detailOstéoporose et sarcopénie: un même combat ?
Locquet, Médéa ULiege; Bruyère, Olivier ULiege; Beaudart, Charlotte ULiege et al

in Ortho-Rhumato (2016), 14(4), 34-36

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la ... [more ▼]

L’ostéoporose et la sarcopénie exposent les individus âgés à un risque accru de chutes et de fractures, mais aussi à une altération de leur qualité de vie, à divers handicaps et à une augmentation de la morbidité et de la mortalité. Elles représentent toutes deux un problème de santé publique grandissant, impliquant également des coûts de santé importants. Certaines études récentes confirment l’existence d’une unité fonctionnelle «os-muscle», concernant notamment ses aspects biologiques, hormonaux, développementaux ou encore génétiques. Actuellement, quelques études scientifiques démontrent également l’existence de voies communes dans la pathogenèse de la perte de masse musculaire et de masse osseuse. Certains auteurs suggèrent que les dysfonctionnements de cette unité fonctionnelle «os-muscle» pourraient éventuellement conduire à une pathologie spécifique, affectant les deux structures et pour lequel le terme «ostéosarcopénie» a été proposé. Cependant, jusqu’à présent, l’étroite relation entre muscles et os reste très peu explorée par les études cliniques en ce qui concerne ses aspects pathologiques et, plus particulièrement, le lien existant entre sarcopénie et ostéoporose, ses déterminants et ses conséquences. Ce manque de connaissances implique donc des retentissements considérables pour les politiques de santé publique, principalement concernant les stratégies préventives et thérapeutiques susceptibles d’être proposées aux personnes âgées. [less ▲]

Detailed reference viewed: 66 (7 ULiège)
Full Text
See detailIl n'est jamais trop tard pour apprendre à (bien) lire ... La revue systématique
Beaudart, Charlotte ULiege; Rabenda, Véronique ULiege; Bruyère, Olivier ULiege

in Ortho-Rhumato (2016), 14(6), 37-40

La revue systématique est généralement utilisée pour synthétiser les résultats de plusieurs études traitant d’un même sujet. Son intérêt est donc grand, particulièrement depuis ces dernières années où le ... [more ▼]

La revue systématique est généralement utilisée pour synthétiser les résultats de plusieurs études traitant d’un même sujet. Son intérêt est donc grand, particulièrement depuis ces dernières années où le nombre d’articles scientifiques publiés dans la littérature explose! La revue systématique est considérée comme une étude de haut niveau de preuve scientifique. En effet, elle se retrouve au sommet de la pyramide de l’evidence-based medicine. Elle est donc, lorsqu’elle est de qualité, d’un niveau de preuve supérieur aux études randomisées contrôlées, aux études de cohortes, aux études cas-témoins… [less ▲]

Detailed reference viewed: 24 (5 ULiège)
Full Text
See detailHet is nooit te laat om (goed) te leren lezen ... Systematic review
Beaudart, Charlotte ULiege; Rabenda, Véronique ULiege; Bruyère, Olivier ULiege

in Gunaïkeia (2016), 21(9), 37-40

Een systematic review of systematisch literatuuronderzoek wordt meestal gebruikt om een samenvatting te maken van de resultaten van meerdere studies over hetzelfde onderwerp. Systematische ... [more ▼]

Een systematic review of systematisch literatuuronderzoek wordt meestal gebruikt om een samenvatting te maken van de resultaten van meerdere studies over hetzelfde onderwerp. Systematische literatuurstudies zijn dus heel belangrijk, in het bijzonder de voorbije jaren, waarin het aantal in de literatuur gepubliceerde artikelen is geëxplodeerd! Een systematic review wordt beschouwd als een onderzoek met een hoog wetenschappelijk bewijsniveau. Het staat aan de top van de piramide van de evidence-based medicine. Als het onderzoek van goede kwaliteit is, heeft het dus een hoger bewijsniveau dan gerandomiseerde gecontroleerde studies, cohortstudies, case-controlstudies… [less ▲]

Detailed reference viewed: 31 (3 ULiège)
Full Text
See detailLes essais de non-infériorité et d'équivalence
Buckinx, Fanny ULiege; Bruyère, Olivier ULiege

in Gunaïkeia (2016), 10

Les essais de non-infériorité, aussi appelés essais d’équivalence clinique, permettent de montrer que l’efficacité d’un nouveau traitement n’est pas trop inférieure à celle du traitement comparateur. Ils ... [more ▼]

Les essais de non-infériorité, aussi appelés essais d’équivalence clinique, permettent de montrer que l’efficacité d’un nouveau traitement n’est pas trop inférieure à celle du traitement comparateur. Ils ne permettent cependant pas de conclure à la stricte équivalence d’efficacité. L’un des prérequis de ces essais est d’accepter une perte d’efficacité pour d’autres avantages. [less ▲]

Detailed reference viewed: 25 (1 ULiège)
Full Text
Peer Reviewed
See detailIncidence of bone fractures after critical illness
ROUSSEAU, Anne-Françoise ULiege; Michel, Laure ULiege; Bawin, Maxime ULiege et al

in Intensive Care Medicine Experimental (2016), 4(Suppl 1), 1131

Detailed reference viewed: 23 (8 ULiège)